HC Wainwright Raises Earnings Estimates for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX) – Stock analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for TG Therapeutics in a report issued on Thursday, February 26th. HC Wainwright analyst E. Bodnar now anticipates that the biopharmaceutical company will post earnings of $0.24 per share for the quarter, up from their prior forecast of $0.23. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for TG Therapeutics’ Q2 2026 earnings at $0.28 EPS, Q3 2026 earnings at $0.34 EPS and FY2030 earnings at $4.01 EPS.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Monday, March 2nd. The biopharmaceutical company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.35 by ($0.21). TG Therapeutics had a net margin of 84.13% and a return on equity of 133.24%. During the same period last year, the business posted $0.15 EPS. The company’s quarterly revenue was up 78.0% on a year-over-year basis.

A number of other brokerages have also recently weighed in on TGTX. B. Riley Financial upgraded shares of TG Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 4th. Wall Street Zen downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. JPMorgan Chase & Co. cut their target price on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a research report on Monday, February 2nd. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research report on Monday, December 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, TG Therapeutics has an average rating of “Moderate Buy” and an average target price of $50.00.

TG Therapeutics Stock Up 4.2%

Shares of TG Therapeutics stock opened at $30.90 on Friday. The stock has a market capitalization of $4.91 billion, a P/E ratio of 11.12 and a beta of 1.85. The company has a quick ratio of 2.89, a current ratio of 3.82 and a debt-to-equity ratio of 0.40. The stock has a 50 day moving average price of $29.87 and a two-hundred day moving average price of $31.40. TG Therapeutics has a 12-month low of $25.28 and a 12-month high of $46.48.

Institutional Trading of TG Therapeutics

A number of hedge funds have recently bought and sold shares of TGTX. Maryland State Retirement & Pension System increased its holdings in shares of TG Therapeutics by 2.0% during the 4th quarter. Maryland State Retirement & Pension System now owns 19,899 shares of the biopharmaceutical company’s stock worth $593,000 after purchasing an additional 393 shares during the period. Signature Wealth Management Partners LLC lifted its stake in shares of TG Therapeutics by 3.7% in the third quarter. Signature Wealth Management Partners LLC now owns 11,180 shares of the biopharmaceutical company’s stock valued at $404,000 after buying an additional 400 shares during the period. Teacher Retirement System of Texas grew its position in TG Therapeutics by 1.0% during the second quarter. Teacher Retirement System of Texas now owns 40,212 shares of the biopharmaceutical company’s stock worth $1,447,000 after buying an additional 417 shares in the last quarter. Amalgamated Bank increased its stake in TG Therapeutics by 1.1% during the third quarter. Amalgamated Bank now owns 39,248 shares of the biopharmaceutical company’s stock valued at $1,418,000 after acquiring an additional 424 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in TG Therapeutics by 1.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,406 shares of the biopharmaceutical company’s stock valued at $1,135,000 after acquiring an additional 441 shares in the last quarter. 58.58% of the stock is owned by institutional investors.

Key Headlines Impacting TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Company raised 2026 total global revenue target to about $875–$900 million, reflecting confidence in BRIUMVI growth; investors typically reward upgraded guidance. TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance
• Positive Sentiment: Strong revenue: Q4 total revenue $192.6M and full-year 2025 $616.3M (BRIUMVI U.S. net revenue $182.7M Q4; $594.1M FY), a ~78% YoY revenue increase that supports valuation and future cash flow expectations. Press Release
• Positive Sentiment: Management commentary emphasized physician adoption and patient retention on BRIUMVI—narrative that can sustain multiple expansion if growth continues. Earnings Call Transcript
• Neutral Sentiment: Company reported net income of $23M (EPS $0.14), but that profit figure comes amid sizable revenue growth—investors will watch sustainability and margin trends. Earnings Snapshot
• Negative Sentiment: EPS missed expectations badly (reported $0.14 vs. consensus ~$0.35; ~-60% surprise), which is a short-term negative and may invite analyst estimate cuts or short-term selling pressure if execution concerns persist. Earnings Miss Coverage
• Negative Sentiment: Despite revenue growth, the sizable EPS shortfall raises questions on cost structure, one-time items or accounting timing; watch forthcoming analyst note revisions and management’s detail on drivers in the call transcript and 10-Q. Earnings Call Transcript (Seeking Alpha)

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.